A rare disease therapeutics company that uses AI to accelerate clinical development and commercialization of breakthrough medicines for diseases with high unmet need
Get in Touch
We believe rare and ultra rare diseases are drastically underserved and require a novel approach to bringing innovation to patients.RarePath will create pathways for scientists to develop cures for rare and ultra-rare disease without perpetual dependence on Pharma M&A.We will do so by partnering with academic researchers, biotech, and patient foundations to fund, license, and commercialize therapies.
Josh brings over two decades of leadership experience building and scaling biotechnology companies, with a focus on rare diseases. He has led multiple companies through successful acquisitions, including Escient Pharmaceuticals (acquired by Incyte) and Modis Therapeutics (acquired by Zogenix). Earlier in his career, Josh spent 15 years at BioMarin, where he played a key role in shaping the company’s rare disease strategy and supporting the global development and commercialization of multiple therapies. Across his career, he has combined company-building, strategic execution, business development, and operational leadership to advance innovative medicines for patients with high unmet need.
Jeff is a seasoned biopharmaceutical executive with more than 25 years of experience leading global commercial organizations across rare disease and specialty medicines. Most recently, he served as Chief Commercial Officer at BioMarin from 2012 to 2024, where he helped build the company’s commercial infrastructure and led the successful global launches of five rare disease therapies. Prior to BioMarin, Jeff held senior commercial leadership roles at Genzyme, SangStat, and ICN Pharmaceuticals. His experience spans launch strategy, global market access, and lifecycle management, with a consistent focus on translating complex science into meaningful patient impact.
Lalarukh brings deep experience at the intersection of life sciences, healthcare, and technology. She previously served as Executive Vice President of Life Sciences and Aerospace at Palantir Technologies, where she spent over a decade driving adoption of AI-driven data platforms across pharma, CROs and healthcare organisations. Her work focused on large-scale data integration, accelerating drug development and commercialization, and modernizing clinical trial operations globally. Prior to Palantir, Lalarukh completed her PhD and postdoctoral research at the University of Cambridge, where her research investigated GPCR drug targets in primary hyperaldosteronism and secondary hypertension.
Greg brings experience across business development, investing, and corporate strategy within the biotechnology space. Most recently, he was an investor at Avego Bioscience Capital, where he focused on evaluating and investing in early- and mid-stage therapeutic companies. Prior to that, Greg led Business Development at Escient Pharmaceuticals (acquired by Incyte) and served as Director of BD at Zogenix (acquired by UCB), supporting a range of licensing, acquisition, and strategic partnership transactions. Earlier in his career, he held roles at Bayer focused on U.S. Business Development & Licensing and Global Mergers, Acquisitions & Licensing, giving him a broad perspective across deal-making and company growth.
We partner with R&D-stage biotech companies to bring high-potential therapies to market. By handling regulatory, clinical, and reimbursement strategy—and putting families at the center—we accelerate delivery of life-saving treatments to the children who need them most.
Mendra helps families access life-saving therapies, empowers scientists to bring discoveries to patients, and gives biotech founders a path to commercialize their most meaningful work.
